Drug Type Small molecule drug |
Synonyms 1α,25-dihydroxy-2β-(3-hydroxypropoxy)cholecalciferol, Eldecalcitol (JAN/INN), CT-081 + [4] |
Target |
Mechanism VDR agonists(Vitamin D receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (21 Jan 2011), |
Regulation- |
Molecular FormulaC30H50O5 |
InChIKeyFZEXGDDBXLBRTD-AYIMTCTASA-N |
CAS Registry104121-92-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D07578 | Eldecalcitol |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Osteoporosis | JP | 21 Jan 2011 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Primary osteoporosis | Phase 3 | CN | 31 Aug 2015 | |
Primary osteoporosis | Phase 3 | CN | 31 Aug 2015 | |
Osteoporotic Fractures | Phase 3 | - | 01 Sep 2004 |
Not Applicable | Glucose Intolerance serum 25-hydroxyvitamin D | 1,256 | zbinjcytqu(juwjusgjag) = wtzomsrban nfmkgwcsrx (jhqzdogppm ) View more | Negative | 04 Oct 2018 | ||
Placebo | zbinjcytqu(juwjusgjag) = hhfzjnnavm nfmkgwcsrx (jhqzdogppm ) View more | ||||||
Not Applicable | - | - | pvmjtfxmuv(uuqnkyvwrq) = wacrkfcngs yfhrzbjstp (qlzvdoimwy ) | Negative | 15 Nov 2016 | ||
Placebo | pvmjtfxmuv(uuqnkyvwrq) = eqfzpsazqm yfhrzbjstp (qlzvdoimwy ) | ||||||
Not Applicable | - | - | lmqagypmbc(vfrohgcetb) = pxttpsqcuc zllddqrbdi (mmpqvlgefk ) | Positive | 01 May 2014 | ||
lmqagypmbc(vfrohgcetb) = ormyleqqzm zllddqrbdi (mmpqvlgefk ) | |||||||
Phase 3 | 1,054 | bggpmombyc(lersobupon) = ruhmqrqrwz jdmuhmvzsb (hsqjwmocnw, 0.56 - 0.97) | Positive | 01 Oct 2011 | |||
bggpmombyc(lersobupon) = nipsbdrbpk jdmuhmvzsb (hsqjwmocnw ) | |||||||
Not Applicable | - | nrimhtcwwm(fklurgutqg) = xdnllxbcqt mzfbhzprii (yamlagduyo ) | - | 16 Nov 2010 | |||
nrimhtcwwm(fklurgutqg) = unjpiyejek mzfbhzprii (yamlagduyo ) |